Search results
Earnings call: MaxCyte sees steady growth and strategic partnerships in Q1 2024
Investing.com· 5 days agoMaxCyte, Inc. (MXCT) reported a solid start to the fiscal year 2024, with total revenue reaching...
As Ozzy Osbourne announces stem cell therapy, experts urge caution, highlight risks
Fox News via Yahoo News· 7 days agoAs rock legend Ozzy Osbourne has turned to stem cell therapy, some experts caution that the...
As Ozzy Osbourne announces stem cell therapy, experts urge caution, highlight risks
Fox News· 7 days agoAs rock legend Ozzy Osbourne has turned to stem cell therapy, some experts caution that it’s not for...
Medical Moment: Car T-Cell Therapy
WNDU 16 South Bend· 2 days agoMedical experts call it a “breakthrough” and “gamechanger” when it comes to cancer treatment. “Immunotherapy has really come on as quite an advance in...
US FDA approves expanded use of Bristol's cancer cell therapy
Reuters via Yahoo Finance· 8 hours agoMay 15 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved the expanded use of Bristol Myers Squibb's cancer cell therapy Breyanzi to ...
Earnings call: Fate Therapeutics reports on clinical progress and finances
Investing.com· 3 days agoThe company's FT819 CAR T-cell therapy showed promise for B-cell-mediated autoimmune diseases, with...
Earnings call: Fate Therapeutics reports on clinical progress and finances By Investing.com
Investing.com· 3 days agoThe company's FT819 CAR T-cell therapy showed promise for B-cell-mediated autoimmune diseases, with...
Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024
ThePress.net· 1 day agoExpanded strategic relationship with Astellas with new research collaboration leveraging Poseida's proprietary allogeneic CAR-T platform to develop cell therapies targeting solid tumors
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 8 hours agoPreliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study Study participant with Non-Hodgkin’s Lymphoma who relapsed within 90 days of anti-CD19 CAR T cell
Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
ThePress.net· 1 day agoKyverna Therapeutics, Inc. (Nasdaq: KYTX), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, ...